Litong Qi
Overview
Explore the profile of Litong Qi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, et al.
JACC Asia
. 2023 Aug;
3(4):636-645.
PMID: 37614541
Background: Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia. Objectives: The purpose of this study was to assess...
2.
Association between basal septal hypertrophy and left ventricular geometry in a community population
Gao L, Ma W, Li M, Yang Y, Qi L, Zhang B, et al.
BMC Cardiovasc Disord
. 2022 Dec;
22(1):579.
PMID: 36587201
Background: Left ventricular (LV) geometry is closely associated with cardiovascular disease; however, few studies have evaluated the relationship between basal septal hypertrophy (BSH) and LV geometry. In this study, we...
3.
Liu L, Zhang B, Yang Y, Qi L, Wang S, Meng L, et al.
Cardiovasc Ultrasound
. 2022 Nov;
20(1):27.
PMID: 36434713
Background: The left atrium (LA) is closely related to left ventricular diastolic function. Two-dimensional speckle tracking strain and strain rate (SR) imaging has been applied in the study of LA...
4.
Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, et al.
JACC Asia
. 2022 Nov;
1(3):411-415.
PMID: 36341216
The aim of the studies was to evaluate the safety, tolerability, and efficacy of tafolecimab, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, in Chinese healthy volunteers and...
5.
Qi L, Chen J, Li X, Qi X, Ding C, Chen X, et al.
Front Cardiovasc Med
. 2022 Sep;
9:888604.
PMID: 36072875
Background: To evaluate the safety and efficacy of hybutimibe plus atorvastatin for lipid control in hypercholesterolemia patients with atherosclerotic cardiovascular disease risk equivalent. Methods: In this double-blind phase III study,...
6.
Chen C, Yang Y, Ma W, Qi L, Zhang B, Zhang Y
BMC Cardiovasc Disord
. 2022 May;
22(1):231.
PMID: 35590247
Background: Left atrial (LA) size is often used as a surrogate marker of LA function in clinical practice, with larger atrial thought to represent a "dysfunctioning" atrium, since there is...
7.
Qi L, Zhang Q, Zheng Z, Pei Z, Mao H, Jiang T, et al.
Vasc Health Risk Manag
. 2021 Sep;
17:571-580.
PMID: 34552329
Introduction: The lipid-modifying potential of omega-3 polyunsaturated fatty acids in Chinese patients is under-researched. We conducted a multicenter, randomized, placebo-controlled, double-blind, parallel-group study of twice-daily treatment with OMACOR (OM3EE), a...
8.
Ma W, Zhang B, Yang Y, Qi L, Zhou J, Li M, et al.
BMC Cardiovasc Disord
. 2021 May;
21(1):262.
PMID: 34049490
Background: We examined the relationship between epicardial fat thickness (EFT) measured by echocardiography and left ventricular diastolic function parameters in a Beijing community population. Methods: We included 1004 participants in...
9.
Ma W, Yang Y, Qi L, Zhang B, Meng L, Zhang Y, et al.
Int J Hypertens
. 2021 Mar;
2021:2920140.
PMID: 33747558
Blood pressure variability (BPV) has been identified as an important risk factor for cardiovascular events. The white coat effect (WCE), which is measured as the first systolic blood pressure (SBP)...
10.
Ma W, Qi L, Fan F, Yang Y, Zhang B, Jia J, et al.
Blood Press Monit
. 2020 Dec;
26(1):60-64.
PMID: 33290301
Objective: The inter-arm SBP difference (IASBPD) can serve as a predictor of cardiovascular disease (CVD). In this study, we aimed to determine the relationship between IASBPD and central blood pressure...